How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

    The content on this page is not current guidance and is only for the purposes of the consultation process.

    Updating technology appraisal recommendations for COVID-19 medicines: revised approach

    Closed for comments This consultation ended on at   Request commenting lead permission

    1 What we heard in the consultation

    • Stakeholders would like more involvement in the process including:

      • The ability to make submissions

      • The ability to nominate patient, clinical and commissioning experts

      • The draft guidance consultation period should be longer

        NICE response: These steps will be added in but lengthen the process

    • Transparency could be increased. For example:

      • Committee meetings should be held in public

      • Review decisions should be made public and consulted on

        NICE response: This will take more resources but given its importance can be implemented

    • The cost-recovery charge is too high and companies should not have to pay for surveillance activity

      NICE response: Changes to the process in response to the consultation are proposed resulting in a different charge (see section 3)

    • The funding time-frame should be reduced from 90 days to 30 days or interim funding should be available

      NICE response: NICE does not have the ability to alter the legal funding timeframe. It is up to commissioners to decide whether to implement recommendations earlier than the 90 day deadline.

    • Concerns about data availability in light of reduced testing/ national data collection

      NICE response: This is a key challenge and there have been further developments since the start of the consultation (see section 2)